Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Short Communication

Volume 12, Number 1, January 2020, pages 36-40


Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis

Figure

Figure 1.
Figure 1. Clinical outcomes at baseline and at 10 weeks in seven patients who received combination therapy TOF and intensive GMA. The mean full Mayo scores (a) and endoscopic sub-scores (b) show significant differences between at baseline and 10 weeks (P < 0.01). The mean full Mayo scores decreased from 8.71 ± 0.80 at baseline to 1.57 ± 0.48 at 10 weeks, and the mean endoscopic subscore decreased from 2.4 ± 0.2 at baseline to 0.6 ± 0.2 at 10 weeks. CRP values (c) show no significant difference between at baseline and 10 weeks (P = 0.20). The mean CRP level decreased from 0.71 ± 0.49 mg/dL at baseline to 0.02 ± 0.005 mg/dL at 10 weeks. The values are presented as means ± standard error values and were made by using paired t-test. *P< 0.01. TOF: tofacitinib; GMA: granulocyte and monocyte adsorptive apheresis; CRP: C-reactive protein.

Tables

Table 1. Baseline Demographic Data of Seven Cases That Received Combination Therapy With TOF and Intensive GMA for Refractory UC
 
Demography
The data are presented as means. TOF: tofacitinib; GMA: granulocyte and monocyte adsorptive apheresis; UC: ulcerative colitis; TNF: tumor necrosis factor; CRP: C-reactive protein.
Male/female (N)2/5
Age (years)53.3
Mean disease duration (years)16.1
Location of lesions (N)
  Extensive3
  Left-sided4
Severity (N)
  Moderate/severe6/1
Concomitant medications for UC (N)
  Corticosteroids/budesonide6
  Mesalamine7
  Azathioprine1
Prior use of anti-TNF-α antibodies (N)4
Full Mayo score at baseline8.71
Endoscopic sub-score at baseline2.4
CRP at baseline (mg/dL)0.71

 

Table 2. Clinical Course Through 10 Weeks
 
No.AgeSexDisease duration (years)Disease locationPretreatedAt baselineTreatedAt 10 weeks
Previous treatmentPSL (mg)Full MayoEndo scoresCRP (mg/dL)TOFIntensive GMAFull MayoEndo scoresCRCRP (mg/dL)PSL (mg)
PSL: prednisolone; Bude: budesonide; CRP: C-reactive protein; ADA: adalimumab; IFX: infliximab; TOF: tofacitinib; GMA: granulocyte and monocyte adsorptive apheresis; CR: clinical remission; AZA: azathioprine.
170M10Left-sidedIFX401233.56++00+0.040
240M4ExtensiveADA401020.99++11+0.040
345F29Left-sidedIFX0630.03++31-0.030
458F22Extensive3720.04++30-0.030
564F32Left-sided5930.16++21+0.010
650F6Left-sidedADA, AZABude 2720.04++21+0.010
746F10Extensive201020.2++00+0.010